Adaptive Biotechnologies Corp
ADPT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.25B
Close$
$-25.38
194.6% downside
Current Fair Value
194.6% downsideOvervalued by 194.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.25 Billion |
|---|---|
| Enterprise Value | $4.55 Billion |
| Earnings per Share | $-0.39 |
| Beta | 2.1 |
| Outstanding Shares | 157,700,126 |
Return
| Return on Equity | -44.68% |
|---|---|
| Return on Assets | -9.97% |
| Return on Invested Capital | -6.60% |
Valuation & Multiples
| P/E Ratio | -65.39 |
|---|---|
| PEG | -118.17 |
| Price to Sales | 26.83 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 14.75 |
| Enterprise Value to EBIT | -124.64 |
| Enterprise Value to Net Income | -72 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 3.24 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$-0.09
Consensus analyst estimateRevenue Estimate
$71.57 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 4, 2027
EPS Estimate
$-0.06
Consensus analyst estimateRevenue Estimate
$79.26 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 0.46% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.97%▼ 396.33% |
|---|---|
| Total Invested | $88.43M▼ 97.37% |
| Investors Holding | 69▼ 241.00% |
About Adaptive Biotechnologies Corp
CEO: Chad Robins
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...